

Pharmaceutical Statistics Using SAS



[Pharmaceutical Statistics Using SAS_ 下载链接1](#)

著者:Dmitrienko, Alex (EDT)/ Chuang-Stein, Christy (EDT)/ D'agostino, Ralph (EDT)

出版者:Sas Inst

出版时间:2007-1

装帧:Pap

isbn:9781590478868

作者介绍:

目录: 1 Statistics in Drug Development 1
By Christy Chuang-Stein and Ralph D' Agostino

1.1 Introduction 1

1.2 Statistical Support to Non-Clinical Activities 2

1.3 Statistical Support to Clinical Testing 3

该百科来自公卫百科 (wiki.epiman.cn)

1.4 Battling a High Phase III Failure Rate 4

1.5 Do Statisticians Count? 5

1.6 Emerging Opportunities 5

1.7 Summary 6

References 6

2 Modern Classification Methods for Drug Discovery 7

By Kjell Johnson and William Rayens

该百科来自公卫百科 (wiki.epiman.cn)

2.1 Introduction	7
2.2 Motivating Example	9
2.3 Boosting	10
2.4 Model Building	27
2.5 Partial Least Squares for Discrimination	33
2.6 Summary	42
References	42
3 Model Building Techniques in Drug Discovery	45
By Kimberly Crimin and Thomas Vidmar	
该百科来自公卫百科 (wiki.epiman.cn)	
3.1 Introduction	45
3.2 Example: Solubility Data	46
3.3 Training and Test Set Selection	47
3.4 Variable Selection	51
3.5 Statistical Procedures for Model Building	58
3.6 Determining When a New Observation Is Not in a Training Set	61
该百科来自公卫百科 (wiki.epiman.cn)	
3.7 Using SAS Enterprise Miner	63
3.8 Summary	67
References	67
4 Statistical Considerations in Analytical Method Validation	69
By Bruno Boulanger, Viswanath Devanaryan, Walthère Dewé, and Wendell Smith	
4.1 Introduction	69
该百科来自公卫百科 (wiki.epiman.cn)	
4.2 Validation Criteria	73
4.3 Response Function or Calibration Curve	74
4.4 Linearity	83
4.5 Accuracy and Precision	85
4.6 Decision Rule	88
4.7 Limits of Quantification and Range of the Assay	92
4.8 Limit of Detection	93
4.9 Summary	93
该百科来自公卫百科 (wiki.epiman.cn)	
4.10 Terminology	94
References	94
5 Some Statistical Considerations in Nonclinical Safety Assessment	97
By Wherly Hoffman, Cindy Lee, Alan Chiang, Kevin Guo, and Daniel Ness	
5.1 Overview of Nonclinical Safety Assessment	97
5.2 Key Statistical Aspects of Toxicology Studies	98
该百科来自公卫百科 (wiki.epiman.cn)	
5.3 Randomization in Toxicology Studies	99
5.4 Power Evaluation in a Two-Factor Model for QT Interval	102
5.5 Statistical Analysis of a One-Factor Design with Repeated Measures	106
5.6 Summary	113
Acknowledgments	115
References	115
该百科来自公卫百科 (wiki.epiman.cn)	
6 Nonparametric Methods in Pharmaceutical Statistics	117
By Paul Juneau	
6.1 Introduction	117
6.2 Two Independent Samples Setting	118
6.3 The One-Way Layout	129
6.4 Power Determination in a Purely Nonparametric Sense	144
Acknowledgments	149
该百科来自公卫百科 (wiki.epiman.cn)	

References 149

7 Optimal Design of Experiments in Pharmaceutical Applications 151

By Valerii Fedorov, Robert Gagnon, Sergei Leonov, and Yuehui Wu

7.1 Optimal Design Problem 152

7.2 Quantal Dose-Response Models 159

7.3 Nonlinear Regression Models with a Continuous Response 165

该百科来自公卫百科 (wiki.epiman.cn)

7.4 Regression Models with Unknown Parameters in the Variance Function 169

7.5 Models with a Bounded Response (Beta Models) 172

7.6 Models with a Bounded Response (Logit Link) 176

7.7 Bivariate Probit Models for Correlated Binary Responses 181

该百科来自公卫百科 (wiki.epiman.cn)

7.8 Pharmacokinetic Models with Multiple Measurements per Patient 184

Pharmaceutical Statistics Using SAS: A Practical Guide v

7.9 Models with Cost Constraints 190

7.10 Summary 192

References 193

8 Analysis of Human Pharmacokinetic Data 197

该百科来自公卫百科 (wiki.epiman.cn)

By Scott Patterson and Brian Smith

8.1 Introduction 197

8.2 Bioequivalence Testing 199

8.3 Assessing Dose Linearity 204

8.4 Summary 209

References 209

9 Allocation in Randomized Clinical Trials 213

By Olga Kuznetsova and Anastasia Ivanova 该百科来自公卫百科 (wiki.epiman.cn)

9.1 Introduction 213

9.2 Permuted Block Randomization 214

9.3 Variations of Permuted Block Randomization 217

9.4 Allocations Balanced on Baseline Covariates 228

9.5 Summary 233

Acknowledgments 233

References 233

10 Sample-Size Analysis for Traditional Hypothesis Testing:

该百科来自公卫百科 (wiki.epiman.cn)

Concepts and Issues 237

By Ralph G. O'Brien and John Castelleo

10.1 Introduction 238

10.2 Research Question 1: Does “QCA” Decrease Mortality in Children with Severe Malaria? 240

10.3 p-Values, α , β and Power 241

10.4 A Classical Power Analysis 243

该百科来自公卫百科 (wiki.epiman.cn)

10.5 Beyond α and β : Crucial Type I and Type II Error Rates 249

10.6 Research Question 1, Continued: Crucial Error Rates for Mortality Analysis 251

10.7 Research Question 2: Does “QCA” Affect the “Elysemine : Elysemate”

Ratios (EER)? 253 该百科来自公卫百科 (wiki.epiman.cn)

10.8 Crucial Error Rates When the Null Hypothesis Is Likely to Be True 262

10.9 Table of Crucial Error Rates 263

10.10 Summary 263

Acknowledgments 264

References 264

Appendix A Guidelines for “Statistical Considerations” Sections 264

该百科来自公卫百科 (wiki.epiman.cn)

Appendix B SAS Macro Code to Automate the Programming 265

11 Design and Analysis of Dose-Ranging Clinical Studies 273

By Alex Dmitrienko, Kathleen Fritsch, Jason Hsu, and Stephen Ruberg

11.1 Introduction 273

11.2 Design Considerations 277 该百科来自公卫百科 (wiki.epiman.cn)

11.3 Detection of Dose-Response Trends 280

11.4 Regression Modeling 289

11.5 Dose-Finding Procedures 294

11.6 Summary 309

References 310

12 Analysis of Incomplete Data 313

By Geert Molenberghs, Caroline Beunckens, Herbert Thijs, Ivy Jansen, Geert Verbeke, Michael Kenward, and Kristel Van Steen 该百科来自公卫百科 (wiki.epiman.cn)

12.1 Introduction 314

12.2 Case Studies 316

12.3 Data Setting and Modeling Framework 318

12.4 Simple Methods and MCAR 319

12.5 MAR Methods 320

12.6 Categorical Data 322

12.7 MNAR Modeling 340

12.8 Sensitivity Analysis 347

12.9 Summary 356

该百科来自公卫百科 (wiki.epiman.cn)

References 356

13 Reliability and Validity: Assessing the Psychometric Properties of Rating Scales 361

By Douglas Faries and Ilker Yalcin

13.1 Introduction 361

13.2 Reliability 362

13.3 Validity and Other Topics 376

13.4 Summary 382 该百科来自公卫百科 (wiki.epiman.cn)

References 383

14 Decision Analysis in Drug Development 385

By Carl-Fredrik Burman, Andy Grieve, and Stephen Senn

14.1 Introduction 385

14.2 Introductory Example: Stop or Go? 386

14.3 The Structure of a Decision Analysis 392

14.4 The Go/No Go Problem Revisited 394 该百科来自公卫百科 (wiki.epiman.cn)

14.5 Optimal Sample Size 397

14.6 Sequential Designs in Clinical Trials 406

14.7 Selection of an Optimal Dose 412

14.8 Project Prioritization 421

14.9 Summary 426

Acknowledgments 426

References 426

Index 429

• • • • • (收起)

[Pharmaceutical Statistics Using SAS 下载链接1](#)

标签

pharmaceutics

Statistics

评论

墙裂推荐的一本书，实操性很强，从临床前到人体试验阶段都有介绍，虽然内容的全面性和深度不是很完美，但是和其他相关书配合起来读还是有很大帮助的。

[Pharmaceutical Statistics Using SAS 下载链接1](#)

书评

[Pharmaceutical Statistics Using SAS 下载链接1](#)